NEWHALL CHARLES W III 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Nov 24, 2025
Insider Transaction Report
Form 4
NEWHALL CHARLES W III
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-21$12.98/sh+15,000$194,700→ 119,644 total - Exercise/Conversion
Director Stock Option (Right to Buy)
2025-11-21−15,000→ 0 totalExercise: $12.98From: 2017-03-01Exp: 2026-03-01→ Common Stock (15,000 underlying)